Search Results
Your search for all items matches 439 pages
Showing 401 - 439Dual-Stained Cytology Has Greater Sensitivity and Comparable Specificity vs Pap Cytology for High-Grade Cervical Intraepithelial Neoplasia
Pap cytology is more specific but less sensitive than human papillomavirus (HPV) testing for the detection of high-grade cervical intraepithelial neoplasia (CIN2+). In the pan-European PALMS study, reported in the Journal of the National Cancer Institute, Hans Ikenberg, MD, of CytoMol in...
Etirinotecan Pegol Shows Activity in Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer
Etirinotecan pegol is a topoisomerase-I inhibitor that prolongs systemic exposure to the active metabolite of irinotecan. In a phase II trial reported in Journal of Clinical Oncology, Ignace B. Vergote, MD, PhD, of University Hospital Leuven in Belgium, and colleagues found that the agent produced...
ECC 2013: Continuous Combined Hormone Replacement Therapy Protects Against Endometrial Cancer
According to an analysis of the Women’s Health Initiative, continuous combined use of estrogen plus progestin reduces the risk of endometrial cancer among postmenopausal women. The study was reported at the European Cancer Congress 2013 in Amsterdam (Abstract LBA13) by Rowan Chlebowski, MD,...
ASTRO: Cisplatin Plus Radiation Therapy for Advanced Cervical Cancer Improves Disease-Free Survival vs Radiotherapy Alone
Adding the chemotherapy drug cisplatin to a treatment plan of radiation therapy and high–dose rate brachytherapy for stage IIIB cervical cancer is beneficial, according to research presented on September 22, 2013, at the American Society for Radiation Oncology’s 55th Annual Meeting...
Reduced Long-Term Survival and Increased Risk of Secondary Cancer in Younger Women After External Pelvic Radiation for Early-Stage Endometrial Cancer
In a study reported in Journal of Clinical Oncology, Mathias Onrud, MD, of Norwegian Radium Hospital, Oslo University Hospital, and colleagues assessed outcomes in the follow-up of the Norwegian Radium Hospital trial to determine long-term effects of external beam radiation therapy in the adjuvant...
Brachytherapy to Treat Cervical Cancer on the Decline in the United States
A study by researchers at Brigham and Women's Hospital found that brachytherapy was associated with better cause-specific survival and overall survival in women with cervical cancer. The population-based analysis also revealed geographic disparities and decline in brachytherapy treatment in the...
Genomic Differences Found in Two Types of Cervical Cancer
A study by Alexi Wright, MD, MPH, and colleagues at Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston has found that two common subtypes of cervical cancer, adenocarcinoma and squamous cell carcinoma, have distinct molecular profiles. The results suggest that clinical...
African American Women Less Likely to Receive HPV Vaccine Than Whites, Study Finds
African American women are less likely to receive the vaccine for human papillomavirus (HPV), even with access to health care, according to a study by researchers at the University of Pittsburgh School of Medicine. The findings, published today in the Journal of Adolescent Health, suggest a need...
New Screening Strategy May Detect Ovarian Cancer at Early Stages
A new screening strategy for ovarian cancer appears to be highly specific for detecting the disease before it becomes lethal. The strategy was described in a study published early online this week in Cancer. A clinical trial is ongoing to verify the findings. Karen Lu, MD, of The University of...
Dose-Dense Paclitaxel Plus Carboplatin Improves Long-Term Survival in Advanced Ovarian Cancer
The primary analysis of the Japanese JGOG 3016 trial showed that dose-dense paclitaxel plus carboplatin significantly improved progression-free and overall survival compared with conventional paclitaxel/carboplatin as first-line treatment in patients with advanced ovarian cancer. In a long-term...
New Study Supports Role of Epithelial-to-Mesenchymal Transition in Patients With Ovarian Cancer
In a study of ovarian cancer cells taken from patients, scientists from Georgia Institute of Technology have confirmed that metastasizing cancer cells have a different molecular structure from primary tumor cells and display genetic signatures consistent with epithelial-to-mesenchymal transition....
CDC Report Shows Stagnated HPV Vaccination Rate for Girls
For the first time since the human papillomavirus (HPV) vaccine became available for adolescent girls in 2006, the vaccination rate for the teenagers has stalled, according to data published in the Centers for Disease Control and Prevention’s (CDC’s) Morbidity and Mortality Weekly...
Study Evaluates Therapeutic Impact of Laparoscopic Para-aortic Staging Surgery before Chemoradiotherapy in Cervical Cancer
In a study reported in Journal of Clinical Oncology, Sebastien Gouy, MD, of Institut Gustave Roussy, and colleagues evaluated survival outcomes in locally advanced cervical cancer patients with negative PET-CT imaging results who underwent laparoscopic para-aortic staging surgery before...
Progesterone and Estrogen Receptor Expression Are Prognostic Markers for Endometrioid and High-grade Serous Ovarian Cancer
Few markers of ovarian cancer prognosis have been established, perhaps because potential subtype associations are missed in studies including patients with all histopathologic subtypes. In a study reported in Lancet Oncology, Weiva Sieh, PhD, of Stanford University and colleagues assessed the...
HPV Vaccine Reduces Prevalence of Oral HPV Infections in Costa Rican Study
A new study by the International Agency for Research on Cancer (IARC), in partnership with Costa Rican investigators and the National Cancer Institute (NCI), shows for the first time that the vaccine against human papillomavirus (HPV) types 16 and 18, which is used to prevent cervical cancer, also...
Most Commonly Used Ovarian Cancer Cell Lines Do Not Resemble Ovarian Cancer
Researchers from Memorial Sloan-Kettering Cancer Center recently discovered that the most frequently used cancer cell lines in ovarian cancer research are not suitable models of ovarian cancer. Their findings are the result of a detailed review of genomic data that recently became publicly...
Novel Drug Combination Shows Activity in Recurrent Ovarian Cancer
A novel pairing of two investigational cancer drugs in patients with recurrent ovarian cancer showed promising activity and had manageable toxicities, according to a phase I trial published online in the European Journal of Cancer. The combination of the poly(ADP-ribose) polymerase (PARP)...
L1CAM Predicts Recurrence and Poor Outcome in Early-stage Type I Endometrial Cancer
Although patients with early-stage type I endometrial cancer have very good prognosis, a substantial proportion experience recurrence and die from the disease. In a study published in Journal of the National Cancer Institute, Alain G. Zeimet, MD, PhD, of Innsbruck Medical University, Austria, and...
Study Shows HPV Vaccine Reduced Rate of Infection in Teenage Girls by 56%
A new government study investigating the prevalence of human papillomavirus (HPV) infections in females aged 14 to 59 before and after the introduction in 2006 of the HPV vaccine found that the rate of the HPV infection dropped by 56%, decreasing from 11.5% in 2006 to 5.1% in 2010 among female...
Trebananib plus Paclitaxel Significantly Delays Disease Progression in Patients with Recurrent Ovarian Cancer
In a phase III trial, treatment with the investigational agent trebananib plus paclitaxel resulted in a statistically significant improvement in progression-free survival in patients with recurrent ovarian cancer, according to Amgen. Trebananib is an investigational peptibody designed to inhibit...
ASCO 2013: Cervical Cancer Screening Using Visual Inspection with Vinegar Reduces Mortality by 31% in Large Study in India
Cervical cancer mortality was reduced by 31% over a period of 15 years among women screened with biennial visual inspection with acetic acid (VIA), or vinegar, delivered by primary health workers in a large randomized study conducted among 150,000 women in India. The researchers estimate this...
ASCO 2013: Adding Bevacizumab to Chemotherapy Significantly Improves Response Rates and Survival in Women with Advanced Cervical Cancer
Adding bevacizumab (Avastin) to chemotherapy regimens with or without a platinum drug improved outcomes for women with metastatic or relapsed cervical cancer treated in a randomized phase III study. Presenting the results at the 2013 ASCO Annual Meeting (Abstract 3), lead author Krishnansu Sujata...
ASCO 2013: No Increased Risk of Oral HPV Infections Reported in Long-term Partners of Patients with HPV-positive Oropharyngeal Cancers
Spouses and long-term partners of patients diagnosed with human papillomavirus (HPV)-positive oropharyngeal cancer were no more likely to test positive for oral HPV infection than people in the general population and have a low risk of HPV-related oropharyngeal cancer, according to the Human Oral...
ASCO 2013: Pazopanib Maintenance Therapy Delays Relapse of Advanced Ovarian Cancer
A phase III clinical trial has found that pazopanib (Votrient), an oral multikinase inhibitor, extends disease-free survival by an average of 5.6 months, compared to placebo, in women with advanced ovarian cancer who had initial successful treatment with surgery and chemotherapy. “Our...
Study: Gold Nanoparticles Can Help Fight Ovarian Cancer
Positively charged gold nanoparticles are usually toxic to cells, but cancer cells somehow manage to avoid nanoparticle toxicity. Mayo Clinic researchers found out why and determined how to make the nanoparticles effective against ovarian cancer cells. The discovery is detailed in the current...
ASCO 2013: PARP Inhibitor Shows Activity in Pancreatic, Prostate Cancers among Patients Carrying BRCA Mutations
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers ...
Study Establishes Basis for Genomic Classification of Endometrial Cancers
A comprehensive genomic analysis of nearly 400 endometrial tumors suggests that certain molecular characteristics, such as the frequency of mutations, could complement current pathology methods and help distinguish between principal types of endometrial tumors, as well as provide insights into...
Novel Drug Combination Showed Antitumor Activity in Patients with Incurable BRCA-deficient Cancers
When given sequentially, two orally available experimental drugs—sapacitabine and seliciclib—worked together to elicit antitumor effects in patients with incurable BRCA-deficient cancers, according to phase I data presented at the AACR Annual Meeting 2013, held in Washington, DC, April...
Novel Two-step Immunotherapy Showed Promise for Patients with Recurrent Ovarian Cancer
A novel two-step immunotherapy approach yielded clinically beneficial responses in patients with advanced ovarian cancer, including one patient who achieved complete remission, according to data from two phase I clinical trials presented at the AACR Annual Meeting 2013, held in Washington, DC,...
New Type of Experimental Drug Active in Platinum-resistant Ovarian Cancers
The antibody-drug conjugate DMUC5754A, a novel member of a relatively new class of drugs, showed activity in women with ovarian cancer, even those with hard-to-treat, platinum-resistant disease, in a phase I trial presented at the AACR Annual Meeting 2013, held in Washington, DC, April 6 to 10....
Mayo Clinic: New DNA Sequences Hone in on Breast, Ovarian Cancer Risk
Researchers at Mayo Clinic Cancer Center have identified new DNA sequences associated with breast cancer and ovarian cancer. The findings, which appear in three studies in the journals PLoS Genetics and Nature Genetics, will help reveal the underlying causes of these diseases and help researchers...
Moffitt Cancer Center Researchers Analyze HPV Vaccination Disparities among Girls from Low-income Families
Researchers at Moffitt Cancer Center and colleagues at the University of Florida studied health-care providers to determine the factors associated with disparities in human papillomavirus (HPV) vaccination among girls, ages 9 to 17, from low-income families. They found that physician vaccination...
More Than 60% of Ovarian Cancer Patients Do Not Receive Recommended Treatment, Study Shows
Women are 30% less likely to die of ovarian cancer if they have guideline-recommended treatment, yet nearly two-thirds of those with the disease do not receive it, often because they are cared for at hospitals that treat a small number of ovarian cancer patients. These are the findings of a study...
Intraperitoneal Chemotherapy Gives Ovarian Cancer Patients Better Chance of Survival
Patients with advanced ovarian cancer who undergo intensive treatment with chemotherapy that bathes the abdomen are significantly more likely to live longer than those who receive standard intravenous (IV) chemotherapy, according to a study that analyzed long-term follow-up from two landmark...
Cervical Cancer Patients More Likely to Survive if Treated at High-volume Medical Facilities
Patients with locally advanced cervical cancer have better treatment outcomes and are more likely to survive the disease if they receive care at a high-volume medical center than patients treated at low-volume facilities, according to research presented at the Society of Gynecologic...
Tackling Tobacco Consumption and Improving Vaccination Access Are Two of the Best Ways to Reduce Global Cancer Burden
Combatting the tobacco industry’s tactics in the world’s poorest countries as well as ensuring the best cancer vaccines are available to those most in need are key in order to reduce the number of cancer deaths worldwide, according to a new report published in the journal Science...
Selumetinib Reported to Benefit Patients with Recurrent Low-grade Ovarian Cancer
Low-grade serous ovarian cancer is less common and aggressive than the high-grade variety, but the disease is exceptionally difficult to treat when front-line therapy fails. "After surgery, with or without presurgical chemotherapy, when low-grade serous ovarian cancer persists or returns,...
Bevacizumab Significantly Improves Survival for Patients with Recurrent and Metastatic Cervical Cancer
Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an interim analysis of a large, randomized clinical trial. The...
Yale Researchers Identify Genes behind Aggressive Endometrial Cancer
In a major breakthrough for uterine serous carcinoma (USC), a chemoresistant, aggressive form of endometrial cancer, researchers at Yale Cancer Center have defined the genetic landscape of USC tumors, findings that point to new treatment opportunities. The collaborative team, which included...
